MAPLE GROVE, Minn. — Upsher-Smith Laboratories Inc. has entered an agreement to sell its AmLactin skin care brand to Sandoz Inc.
Financial terms of the deal weren’t disclosed. Upsher-Smith said the move is part of its strategy of focusing on generic drugs and novel therapies.
AmLactin is formulated to gently exfoliate and relieve dryness associated with keratosis pilaris, diabetes, changes in weather, and harsh soaps or detergents. AmLactin alpha hydroxy therapy is said to have more than three times the concentration of lactic acid, a powerful AHA, than in other top-selling therapeutic moisturizers.
The line includes a daily moisturizing body lotion, Rapid Relief restoring lotion plus ceramides, Ultra Smoothing intensely hydrating cream, and Foot Repair foot cream therapy.
The line’s formulas “deeply moisturize and boost the skin’s natural renewal process through gentle exfoliation,” says the brand’s website. “While alpha hydroxy therapy may irritate sensitive skin, AmLactin moisturizers are pH balanced, making reactions less likely.”